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Abstract:
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that
has become the sixth leading cause of death in the United States. The most notable
neuropathological hallmarks of AD are the accelerated accumulation of β-amyloid
deposits around neurons and the accumulation of neurofibrillary tangles (NFT) within
neurons. These abnormalities block proteasome function, inhibit mitochondrial
function, alter biometal levels, stimulate inflammatory processes, disrupt synaptic
communication, and ultimately result in cell death. Mitochondrial dysfunction has
been cited as an underlying cause of AD pathologies, specifically by enhancing the
production and accumulation of β-amyloid. Once the β-amyloid oligomers form, they
disrupt the Ca2+ signals of the astrocytes by forming calcium ion channels or
influencing the existent calcium ion channels. The calcium disruption causes
glutathione depletion, which leaves cells susceptible to further damage by oxidative
stress. Oxidative stress, also enhanced by the mitochondrial dysfunction, has been
extensively reported as having a major role in the development of
neurodegenerative diseases. Thus, a vicious cycle ensues in which oxidative stress
further enhances AD pathologies and further damages the neurons and astrocytes.
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Introduction to Alzheimer’s Disease
Alzheimer’s Disease (AD) is the most common cause of dementia in elderly
populations, accounting for 60 to 80 percent of all reported dementia cases. It is the
sixth leading cause of death in the United States. This progressive
neurodegenerative disorder is characterized by gradual memory loss, a decline in
cognitive function and deterioration of physical function (1).
The greatest risk factor for Alzheimer’s Disease is age- the majority of people
diagnosed are over 65 years old. However, in about 5% of AD cases, early onset
Alzheimer’s Disease appears when a person is in their 40’s or 50’s. In the early
stages of the disease, cognitive function declines and memory loss is mild.
However, as the disease progresses over a few years, people eventually lose their
ability to do daily tasks and engage in everyday conversations. The average life
expectancy of someone diagnosed with AD is eight years. Ultimately fatal, this
disease currently has no known cure (1).
The most notable neuropathological hallmarks of AD brains are the
accelerated accumulation of β-amyloid deposits around neurons and the
accumulation of neurofibrillary tangles (NFT) within neurons. β-amyloid are
misfolded proteins that accumulate in the neuronal space of the brain. NFT are
aggregations of hyperphosphorylated tau protein found accumulated inside the
neurons of AD brains. These abnormalities block proteasome function, inhibit
mitochondrial function, alter biometal levels, stimulate inflammatory processes,
disrupt synaptic communication, and ultimately result in cell death (1).
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Neurons are the specialized cells in the brain responsible for the processing
and transmission of information. The basic function of neurons- transmission of
impulses- is disrupted by the AD pathology. Astrocytes, specialized cells also found
in the brain, are responsible for supporting brain homeostasis. They primarily
provide structural and metabolic support for the neurons. The function of astrocytes
is also disrupted in many neurodegenerative diseases like AD. Apoptosis of
astrocytes disrupts neurotransmitter homeostasis, synaptic transmission, and
neuronal viability (2).
AD pathology begins in the entrorhinal cortex of the brain, a region deep in
the brain connected to the hippocampus. Then, it spreads to the hippocampus, the
region of the brain that is involved in the processing of short-term memory and plays
a major role in learning. Eventually, the AD progresses to other areas of the cerebral
cortex. This includes, the medial parietal, lateral parietal, medial prefrontal, and
medial temporal lobes. All of these areas of the brain play a role in episodic memory
retrieval and encoding (3).
The progression of AD has been classified into three stages: a preclinical
stage in which the disease is asymptomatic, a mild cognitive impairment (MCI) stage
in which cognitive function declines, and a dementia stage (4).
It is believed that an AD brain begins deteriorating 10 to 20 years before any
symptoms or clinically detectable signs emerge. During this preclinical stage, it is
assumed that the AD pathology is causing damage to the brain, despite the fact that
there are no manifested symptoms. As AD spreads throughout the brain, plaques
and tangles develop, neuronal death occurs, brain shrinkage progresses, and more
of the cerebral cortex is affected (5).
Cognitive decline is a normal consequence of aging. However, MCI is defined
as a cognitive decline that is greater than expected for a healthy person of
comparable age. MCI manifests itself in symptoms like: memory loss, confusion in
familiar places, poor judgment, and personality changes. Although MCI is a step in
the progression of AD, not all patients experiencing MCI will develop AD. Some
patients with MCI never progress far enough to be diagnosed with dementia. Other
MCI cases can develop into other dementia types, like Parkinson’s disease or
vascular dementia (6).
As AD progresses into the dementia phase, AD has spread to nearly all areas
of the cerebral cortex controlling language, conscious thought, sensory processing,
and reasoning. As the symptoms become more prevalent, the affected areas
continue to shrink and the ventricles enlarge. Patients experience more severe
symptoms, for example, shortened attention span, difficulty with language, loss of
impulse control, and the inability to perform daily tasks. Ultimately, with severe AD,
patients are entirely dependent on other people for their care. They have difficulty
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swallowing, lose control of their bladder and bowels, and most frequently end up
dying of aspiration pneumonia. This specific type of pneumonia develops as a result
of the inability to properly swallow. The gradual progression of AD in a patient over
the years results from a combination of genetic, biological, environmental, and
lifestyle factors (5).
β-amyloid Deposits
β-amyloid is an insoluble, toxic polypeptide protein of about 39 to 43 amino
acids. Unique to AD, β-amyloid accumulates into plaques and then into oligomers.
These insoluble proteins clusters are found in the neuronal space of the brains of
AD patients and block neuron function (7).
β-amyloid accumulates as a result of an error in a pathway that cleaves
transmembrane Amyloid Precursor Protein (APP) into sAPPα. sAPPα is an
important peptide fragment involved in promoting neuronal survival and growth. In
the benign pathway, a protein called alpha-secretase cleaves APP. This releases
sAPPα into the intracellular space. The remaining APP fragment, still embedded in
the membrane, is cleaved by gamma-secretase. The smaller of the two fragments is
released into the intracellular space, while the larger fragment enters the cytosol,
eventually interacting with the nucleus (1).
In the alternative, harmful pathway, a third APP-cleaving enzyme, betasecretase, cleaves the APP molecule at a different location, releasing a shorter
sAPPα peptide. This leaves a larger polypeptide behind, still attached to the
membrane. This segment of amino acids contains the entire β-amyloid sequence.
Gamma-secretase then cleaves the remaining fragment, releasing the β-amyloid
peptide into the intracellular space. These β-amyloid peptides begin to accumulate
into insoluble oligomers and eventually form the plaques associated with AD (1). βamyloid clearance by the central nervous system appears to be impaired in AD
patients, further accelerating the accumulation of plaques (8).
β-amyloid oligomer density has a significant correlation with cognition
performance. The aggregation of β-amyloid is neurotoxic. β-amyloid plaques have
been directly associated with mitochondrial damage, oxidative stress, reduction in
antioxidants, and destabilization of calcium ion homeostasis. In vitro, β-amyloid
activates apoptotic pathways, ultimately leading to neurodegeneration. β-amyloid
has been shown to interact with redox factor-1, which plays an important role in cell
death signaling pathways and DNA repair (7).
One theory of β-amyloid toxicity is known as the “Amyloid Cascade
Hypothesis”. It assumes that β-amyloid is the main cause and driving force behind
the AD pathologies in the brain. The idea is that β-amyloid oligomers form in the
brain, disrupt the function of the neurons, and directly or indirectly kill the neurons.
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According to this hypothesis, because β-amyloid formation is the cause of both
familial AD (FAD) and late onset AD (LOAD), removing β-amyloid or preventing βamyloid plaque formation is the best approach to preventing and treating AD (7).
However, there is still no clinical evidence that indicates a strong correlation
between plaque buildup and the degree of cognitive decline during AD. This would
suggest that β-amyloid may not necessarily be the direct cause of the cognitive
inhibition. Thus, there is still debate as to whether β-amyloid plaques are responsible
for all neuronal damage associated with AD (8).
Neurofibrillary Tangles
The accumulation of neurofibrillary tangles within neurons is due to
hyperphosphorylated tau proteins (7). Tau, or tubulin-associated unit, is a protein
essential in the process of microtubule assembly. Tau protein is primarily found in
the axons of the central nervous system neurons, but is also found in small
concentrations in somatodendrite areas of neurons, in oligodendrocytes (cells
responsible for axonal management and generation of myelin sheath), and in some
non-neural tissues (9).
Tau proteins promote the assembly of microtubules and play a role in their
stabilization. In normal cells, tau proteins are phosphorylated by protein kinases at
multiple sites. The phosphorylation of the tau protein regulates its biological activity
(9). In AD, an abnormal number of additional phosphates are added to the tau
protein, causing the tau proteins to release from the microtubules. These
hyperphosphorylated tau proteins bind with one another and form tangles within the
cell, known as neurofibrillary tangles (NFT) (1). NFT are made up of abnormal
filaments, wound helically around one another. The detachment of the tau proteins
from the microtubules can cause the microtubules to disintegrate, collapsing the cell
and disrupting the intercellular transport system. This phenomenon is not unique to
AD. Unlike the β-amyloid plaques, neurofibrillary tangles are also observed in other
neurodegenerative conditions like progressive supranuclear palsy, corticobasal
degradation, and frontotemporal dementia. The presence of NFT alone is sufficient
to cause dementia (9).
Braak and Braak used classical silver staining and immunohistochemical
staining of hyperphosphorylated tau to show the gradual accumulation of NFT in
neurons in AD patients. A clear association between NFT and cognitive impairment
was found, further supporting the significance of tau pathology in symptoms of
Alzheimer’s Disease. The Braak staging system breaks down the progression of AD
as associated with NFT into six distinct stages. The appearance of NFT in specific
areas of the brain correlated with the impairment of specific brain related functions.
For example, stage I and II, marked by NFT progression from the transentorhinal
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region to the hippocampus, clinically correlates with the impairment of short term
memory and with mild special disorientation. The research by Braak and Braak
ultimately showed that the neuronal damage associated with AD begins well before
clinical symptoms appear. Current research suggests this is due to the reduced
ability of the neurons to get rid of misfolded, aggregated tau proteins that increase
with advancing age (9). The accumulated NFT impair axoplasmic transport, the
movement of proteins, vesicles, and organelles throughout the cell body. This
ultimately leads to slower, impaired degradation of these abnormal accumulations of
NFT (10).
Link Between NFT and β-amyloid Deposits
Although NFT and β-amyloid are the two hallmarks associated with AD, the
exact connection between the two remains uncertain. Recent data has suggested
that β-amyloid-induced neurotoxicity and synaptic failure results in tau
phosphorylation. This would suggest that the β-amyloid somehow causes, or
induces, the hyperphosphorylation of tau. Several studies support this hypothesis. βamyloid plaques accelerate the formation of NFT in both tau transgenic mice and in
cultured neurons. β-amyloid isolated from AD brains induced neuritic dystrophy
resulting from abnormal tau phosphorylation (8).
Genetics of Alzheimer’s Disease
Incidences of AD are classified into two different categories: Familial
Alzheimer’s Disease (FAD) and Sporadic Alzheimer’s Disease (SAD). Early-onset
AD is a rare form of AD that affects people between the ages of 30 and 60. Most of
the early onset cases have genetic link. In some cases, early-onset AD is inherited
as an FAD mutation. With these gene mutations, there is a clear genetic
predisposition to developing AD. Usually, there is an autosomal dominant mutation
in the amyloid precursor protein (APP) gene on chromosome 21, in the presenilin
protein 1 (PSEN1) gene on chromosome 14, and/or in the presenilin protein 2
(PSEN2) gene on chromosome 1 (1). Mutations in PSEN1 and PSEN2 cause a
partial loss of function in the gamma-secretase enzyme. This accelerates the
production and accumulation of β-amyloid (20). Over 200 different mutations have
been identified as being connected to FAD (1). These mutations contribute to this
hereditary form of AD. The genes trigger the toxic β-amyloid cascade, which results
in significant accumulation of the β-amyloid plaques (5).
Late-onset AD is much more common than early onset AD, accounting for
about 95% of cases. Late-onset AD occurs in people over the age of 60. It is
classified as SAD because mutations in the genes of FAD rarely play a role in the
development of late-onset AD (5).
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However, a gene called APOE, located on chromosome 19, has been linked
to the development of late-onset AD (5). The APOE gene codes for a protein called
Apolipoprotein E, which is the most prevalent lipoprotein in the brain (12). It is a
major cholesterol carrier that regulates lipid transport and injury repair in the brain. It
binds to several cell membrane receptors and delivers lipids to the cells.
Apolipoprotein E has also been shown to bind to β-amyloid proteins and to NFT
(13). Positron Emission tomography (PET) scans have shown that APOE is
deposited in both NFT and β-amyloid plaques (12).
The APOE gene has three alleles, ε2, ε3, and ε4. The presence of the APOE
ε4 allele results in a 2 to 3 fold higher risk of developing SAD. Furthermore, a person
with two APOE ε4 alleles has an earlier onset and 12-fold higher risk of developing
SAD than those individuals that are heterozygous, carrying only one APOE ε4 allele
(3). On the other hand, individuals carrying the ε2 allele have a decreased risk of
developing AD (13).
The exact cause of the link between the APOE alleles and AD remains
unknown. However, the presence of the APOE ε4 alleles is clearly associated with
the accumulation of β-amyloid and with hippocampus atrophy (3). APOE ε4 carriers
also exhibit reduced glucose metabolism in neurons and increased inflammation in
the brain (12). Although the exact mechanism of the Apolipoprotein E remains
elusive, it has been hypothesized that the effects are related to this protein’s
regulatory role in tau phosphorylation, its function in the cell membrane repair and
maintenance, and/or its affect on β-amyloid clearance (3).
Recent mice and human studies have shown that the presence of the APOE
ε4 allele also has an effect on normal brain function, even in young subjects- both in
mouse and human studies. Young mice without AD but with the presence of the
APOE ε4 allele had task-specific spatial learning deficits. They also exhibited
structural changes to presynaptic and postsynaptic compartments of the neurons,
especially in the hippocampal regions. In human studies, young individuals with the
APOE ε4 allele are less proficient at certain behavioral tasks than the APOE ε4
negative individuals. In addition, MRI scans show the inheritance of APOE ε4
causes specific changes in the brain activity in the medial temporal lobe (13). This
research would suggest that the Apolipoprotein E protein plays a significant role in
the cognitive abilities of a person.
Alzheimer’s Disease Research: Obstacles and Limitations
The major obstacle scientists have in the research of AD is the lack of a
sufficient in vitro or in vivo model. Currently, transgenic mouse models are used,
which contain specific mutations in FAD genes. FAD genes are known to contribute
to hereditary AD. However, even these models do not perfectly mimic a patient with
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AD. A model with mutations in the in the APP or presenilin-1 or -2 gene can cause
plaque formation as well as synaptic and memory deficits (14). However, these
mutations fail to develop the NFT pathology and associated neuronal death. No
model developed thus far has been able to replicate both β-amyloid and NFT
pathology. Therefore, this complication has made it more difficult for researchers to
pinpoint an exact mechanism of AD (3).
Oxidative Stress
Free radicals, specifically reactive oxygen species (ROS) and reactive
nitrogen species (RNS), are an inevitable byproduct of biological processes. Free
radicals are atoms or groups of atoms that have unpaired valence electrons, formed
during many different reactions in the body. Although ROS and RNS play an
important role in biological cell signaling, excess amounts of ROS or RNS ultimately
damage cells by causing lipid peroxidation, DNA/RNA oxidation, and protein
oxidation (15).
Living organisms have a natural, built in defensive system against damage
caused by free radicals. Antioxidants are molecules that inhibit the oxidation of other
molecules by scavenging for, and neutralizing free radicals. This prevents the free
radicals from doing damage to the cells (15).
Oxidative stress is an imbalance between the production of free radicals and
the capability of the cells to get rid of, or neutralize, the free radicals. Oxidative
stress occurs when free radical production exceeds the ability of biochemical
pathways to scavenge these free radicals. This can be a result of overproduction of
free radicals, or not enough production of antioxidants. When cells are in a state of
oxidative stress, they are very susceptible to damage (15).
Oxidative Stress and Alzheimer’s Disease
ROS and RNS are unstable and are very reactive with other biomolecules.
They can interact with and damage other biomolecules- lipids, proteins, and
DNA/RNA. Increases in the amount of oxidative stress has already been linked with
aging, as well as vascular diseases- both risk factors for AD. It has also been
extensively reported that free radicals are pathologically important in the
development of several neurodegenerative diseases, not just AD. Several studies
have reported abnormally high levels of lipid peroxidation, DNA/RNA oxidation, and
protein oxidation in AD patients (4).
Lipid peroxidation products are produced when lipids are attacked by ROS
through a free radical reaction mechanism (4). The peroxidation of membrane lipids
can impair cellular functions and cause the membrane to lose both fluidity and
elasticity. Increased incidences of lipid peroxidation have been linked with many
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health issues, including asthma and hepatic cirrhosis. Lipid peroxidation can be both
mutagenic and carcinogenic (16). Specifically in AD, oxidized cholesterol has been
shown to be a significant contributor to neuronal damage and the progression of AD
pathology (15).
Protein oxidation can result from either direct attack by ROS or can result
indirectly from glycoxidation and lipid peroxidation-lipid product binding. Protein
oxidation damages the proteins and can cause a loss of function. The damaged
protein molecules can interrupt a variety of cellular pathways and ultimately
contribute to various diseases and disorders (16). High levels of protein oxidation
has been found in the areas of the brain affected most severely by the AD
histopathology- like the inferior parietal lobe and hippocampus. In contrast, there are
low levels of protein oxidation in areas of the brain with low β-amyloid concentration,
such as the cerebellum (15).
DNA and RNA can be damaged by oxidative species in three distinct ways:
damage can be caused directly to the individual bases, damage can result in strand
breakage, and damage can cause distortion of the helical structure of DNA. The
modified DNA and RNA bases can result in a variety of genetic defects. The high
prevalence of apoptosis observed in AD patients is directly triggered by DNA
damage caused by oxidative stress (1).
The brain is particularly susceptible to oxidative stress because of the high
rate of oxygen consumption by the cells of the brain. Of the oxygen respired by a
person, 25% of it is utilized in the brain. This significant neuronal demand for energy
is mostly due to the continued need to maintain ion gradients across plasma
membranes. The high demand for oxygen increases the chance of creating free
radicals, specifically superoxide (O2-), and hydroxyl (HO-). Also, the brain has a high
concentration of easily oxidized lipid species, which leads to higher rates of both
lipid peroxidation and cholesterol oxidation. Beginning in the earliest stages of AD,
the brain tissue is exposed to oxidative damage, this continues throughout the entire
progression of the disease (15).
Within the brain, neurons are the cells that are most susceptible to ROS and
RNS. The survival of these oxidized neurons depends on the antioxidant action of
astrocytes. Astrocytes are cells that are important in providing structural and
metabolic support for neurons (17). However, in comparison to other organs in the
body, the brain has relatively low levels of antioxidants (18).
There are several studies that confirm a direct link between oxidative stress
and AD. Increases in oxidative stress markers in the brain coincide with the
progression of AD, suggesting that progression of AD might be related to the
increase of ROS. The exact mechanisms underlying the disruption in ROS balance
remain elusive. Support of oxidative stress as a cause of AD includes a study in
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which levels of antioxidants decreased and extent of lipid peroxidation increased in
triple-transgenic mice before the appearance of β-amyloid plaques and NFT.
Furthermore, in vitro studies, oxidative stress has been found to directly promote
both tau hyperphosphorylation and the aggregation of β-amyloid (17).
At the same time, there is a lot of evidence that oxidative stress is further
enhanced by the tau hyperphosphorylation and by the aggregation of β-amyloid. As
potent generators of ROS and RNS, β-amyloid plaques are a known promoter of
oxidative stress. Within the sequence of β-amyloid, it has been suggested that the
amino acid met-35 plays a role in promoting oxidative activity. When replaced by a
cysteine residue in one study, oxidative stress induced by β-amyloid plaques
dramatically declined (14). The formation of β-amyloid oligomers has been shown to
further cause peroxidation by inserting themselves into lipid bilayers, causing
oxidative damage to proteins and other biomolecules. It has also been observed in
cultured neurons and in vivo mouse models that β-amyloid plaques cause an
increase in oxidative stress that subsequently phosphorylates tau at the T231
residue (15).
Another indication of the link between AD and oxidative stress is the
observation of decreased levels of antioxidants in patients with AD. In many reports,
defects in the antioxidant defense mechanisms caused increased oxidative stress,
further facilitating β-amyloid plaque deposition (15).
It has been suggested that β-amyloid deposition could be a protective
response to neuronal damage (19). Because β-amyloid accumulation and oxidative
damage are negatively correlated, β-amyloid plaques may be a compensatory
response of the brain, intended to reduce oxidative stress. This theory could explain
why immunization studies that decreased overall levels of β-amyloid plaques in AD
brains show no improvement in cognitive function. To date, no treatments aimed at
β-amyloid removal have been successful, suggesting that β-amyloid may not be the
most appropriate therapeutic target (8).
Glutathione
Currently, definitively diagnosing a patient with AD is very difficult. Thus,
determining specific biomarkers associated with AD, aside from β-amyloid and NFT
will allow for early onset diagnosis and can potentially point to the underlying
mechanisms of AD. Because of the short half-life of ROS, levels are difficult to
measure directly. Measuring levels of antioxidants or antioxidant enzymatic activity
can be used to determine about of ROS damage (4). Antioxidants are any
substance that delays or prevents oxidation of substrates by scavenging oxidizing
radicals or by regenerating oxidized biomolecules. Antioxidants play a key role in
minimizing oxidative stress (18).
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Studies looking at oxidative stress in AD patients have discovered decreased
levels of glutathione (GSH), a specific antioxidant (20). Overall antioxidant levels in
the brain are lower than other areas of the body. However, within the brain, GSH is
the antioxidant present at the highest concentration. GSH plays a vital role in the
maintenance of the function of brain cells. A decrease in brain level GSH has been
associated with increased oxidative damage in the neurons. This ultimately
increases apoptotic signaling and initiation of cell death. Both in vitro and in vivo
studies have displayed a connection between GSH reduction and AD (17).
The application of β-amyloid to cell cultures led directly to GSH depletion in
multiple types of cell cultures. Specifically, when β-amyloid was added to neurons
and astrocytes, GSH depletion was induced (21). In an in vivo transgenic AD mouse
model, the ratio of GSH to the oxidized form, glutathione disulfide (GSSG), in the
blood, was monitored over time. The GSH/GSSG ratio in the brains of the mice
decreased with the increase in AD pathology. This indicated a rise in oxidative
stress. The GSH/GSSG ratio decreased before the onset of β-amyloid plaques. That
was followed by an overall increase in the amount of GSSG but a continued
decrease in the GSH/GSSG ratio. The increase in GSSG is a compensation
mechanism for the increase in ROS. However, the relative levels of GSH continue to
decrease (17).
There are several GSH related enzyme pathways that were also shown to
change with AD pathology. Glutathione-S-transferase (GST) is an enzyme that
catalyzes a reaction between a nucleophilic compound, such as 4-Hydroxynonenal
(HNE), and GSH. The ultimate purpose of the enzyme is to detoxify the cells by
getting rid of the GSH. It has been found that GST levels are significantly reduced in
key areas of the brains of autopsied AD patients (22). In these same autopsied
patients, mRNA levels of glutathione reductase enzymes, involved in GSH
antioxidant activity with free radicals, are increased in certain areas of the brains.
This mRNA increase is most likely the cell’s way to attempt to compensate for the
GSH depletion (17).
Specifically, mitochondrial GSH plays a critical role in the overall defense of a
cell against oxidative stress. About 10-15% of the total cellular GSH is accounted for
in the mitochondria. The mitochondria does not produce the GSH, rather it must be
taken up from the cytoplasm first. When GSH is oxidized to GSSG, it cannot be
exported from the mitochondria back into the cytoplasm. Ultimately, the presence of
the highly reactive GSSG can inhibit mitochondrial function by interacting with
proteins (18).
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Changes in Intracellular Calcium and Glutathione
Recently, β-amyloid plaques have been shown to form pores in artificial
membranes. β-amyloid has effects on ion selective channels, most notably, voltage
gated calcium channels. It has been suggested that β-amyloid aggregations are
directly inserted into the plasma membranes of astrocytes and initiate sporadic Ca 2+
signals. The β-amyloid either forms calcium ion channels or influences the existent
calcium ion channels. In the study, “Changes in Intracellular Calcium and
Glutathione in Astrocytes as a Primary Mechanism of Amyloid Neurotoxicity”, by
Abramov et al. examines Calcium signal levels in cells treated and not treated with
neurotoxic β-amyloid fragments (23).
The results show that β-amyloid causes sporadic fluctuations of Ca2+ in
astrocytes, but not in nearby neurons. Proper maintenance of calcium levels in
neurons is very important for neuronal signaling. Thus, the maintenance of proper
calcium levels is also important for brain function, including the processes involved
in learning and memory (23).
The increase in Ca2+ concentration observed in this study was not monotonic.
The results showed transient Ca2+ signals, suggesting that the formed channels
quickly dissociate or that there is a low probability that the β-amyloid will affect the
calcium ion channels. It was previously found that the stability of β-amyloid in
membranes is very easily disturbed. For example, it was found that in membranes
that have increased levels of cholesterol, the beta sheet formation was favored over
the alpha helix formation of β-amyloid (23).
These results would suggest that the β-amyloid affects the astrocytes, but not
directly the neurons. However, astrocytes play a vital role in maintenance of the
neurons, thus impaired neuronal viability was observed. Although astrocyte cell
death was not directly caused by the insertion of β-amyloid into the membranes,
calcium-dependent glutathione depletion was observed, indicating disturbed levels
of antioxidants. GSH depletion leaves the cells more susceptible to damage by
oxidative stress. Thus, this study ultimately concludes that the β-amyloid cause a
direct decrease in GSH, by interrupting the calcium levels in the astrocytes (23).
Oxidative Stress and Mitochondrial Dysfunction
The progressive impairment of mitochondrial function has often been linked to
normal aging process (24). Mitochondria are the major source of cellular energy.
Dysfunctional mitochondria are less efficient at producing ATP and this
subsequently leads to problems within the cells (3). Damaged mitochondria disrupt
apoptosis-related proteins. As a result, dysfunctional mitochondria often result in
increased rates of apoptosis (25).
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Mitochondria are very vulnerable to damage by oxidative stress. Ultimately,
oxidative stress has been labeled as one of the main contributors to mitochondrial
dysfunction. There is much evidence that shows greater amounts of lipid
peroxidation, proteins oxidation, and oxidative damage to mitochondrial DNA when
compared with other organelles of the cell (25). Furthermore, mitochondria are also
a major source of ROS generation. Electron leakage across the electron transport
chain in the mitochondria produces superoxide anion, which accounts for 90% of
endogenous ROS. Thus, damaged mitochondria are even more prone to generating
ROS (4).
Several studies have found a significant amount of dysfunction in the
mitochondria of neurons in patients with AD. This dysfunction is specifically linked
with oxidative stress. Compared to an elderly control group, individuals with AD
demonstrate significantly higher levels of oxidative damage in the mitochondria (25).
Almost all aspects of mitochondrial function are impaired in AD. One of the
most documented abnormalities in AD is the reduced energy metabolism of
neurons. This indicates a decrease in the ability of the mitochondria to produce ATP.
Key enzymes for oxidative metabolism (i.e. pyruvate dehydrogenase complex,
cytochrome oxidase, and α- ketoglutarate dehydrogenase complex) show reduced
expression or reduced activity in AD patients (25).
Mitochondria also perform a central role in calcium homeostasis. As high
capacity Ca2+ sinks, excessive uptake of Ca2+ has been associated with increased
production of ROS, inhibited ATP synthesis, and increased signaling for apoptosis
(25).
Mitochondrial Cascade Hypothesis
One group of researchers, Swerdlow, Burns, and Khan, have proposed a
mechanism known as “Mitochondrial Cascade Hypothesis” that specifically links the
deterioration of mitochondrial function with AD pathology. As stated above,
mitochondrial dysfunction has already been linked with the normal aging process.
However, this hypothesis suggests that the underlying cause of AD and AD
pathology is an accelerated, or abnormal, deterioration of mitochondrial function.
Once the mitochondrial dysfunction reaches a certain threshold, the histological
changes associated with AD are triggered (4).
The Mitochondrial Cascade Hypothesis is broken down into three parts.
Firstly, gene inheritance defines the baseline function of an individual’s
mitochondria. This means that the mitochondrion of each individual has an inherent
level of function. Both parents contribute to an offspring’s AD risk, but mothers
contribute more since mitochondrial DNA is inherited maternally (4).
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Secondly, the age at which mitochondrial deterioration manifest is affected by
both environmental and inherited factors. Much research has concluded that
mitochondrial changes are the main driving force behind many aging phenotypes.
Thus, the belief is that the more durable the mitochondria, the slower the brain aging
process (4).
Thirdly, both an individual’s baseline mitochondrial function and their
functional change rate influences the chronology of AD. For example, those
individuals with low baseline function and fast rates of mitochondrial decline, would
be expected to develop AD histology at a younger age than individuals with high
baseline function and slow rates of mitochondrial decline (4).
This hypothesis expands on the previously defined “Amyloid Cascade
Hypothesis” by suggesting that in late onset AD, it is mitochondrial dysfunction that
affects APP expression and processing, as well as β-amyloid accumulation. This
idea, that mitochondrial dysfunction is the root cause of AD, is supported by 1990s
studies that showed mitochondrial dysfunction, as induced by toxins, pushed APP
processing towards β-amyloid production. Furthermore, it is suggested that the
mitochondrial dysfunction could produce other AD associated phenomena, like
increased levels of oxidative stress markers, increased phosphorylation of the tau
proteins, and increased inflammation in the brain (4).
Treatment Aimed at Alleviating Oxidative Stress: Orientin
Because of the clear link between oxidative stress and AD, recent studies
have looked at using antioxidants as an effective treatment option for AD. In a 2015
study by Linju Yu, et al., the researchers studied the effectiveness of a therapy
aimed at reducing mitochondrial dysfunction that is known to lead to oxidative stress
in AD (25).
Erthyroid 2-related factor 2 (Nrf2), a transcription factor, enhances a cells
defense against oxidative stress. Kelch-like ECH-associated protein 1 (Keap1) binds
to Nrf2 to inhibit activation. Downstream of this activation, heme oxygenese-1 (HO1) has been shown to play a neuroprotective role in the cytotoxicity induced by βamyloid because of its redox properties. HO-1 is one of the most selective and
sensitive antioxidant enzymes, known to play a significant large role in
neuroprotection (25).
Nrf2 expression levels have been closely linked with AD brains. Nrf2 levels in
the nuclei of the hippocampus are lower than normal in the brains of AD patients. At
the same time, neurons that express Nrf2 are more protected from oxidative stress
induced by β-amyloid. Furthermore, HO-1 mRNA and protein levels are significantly
lower in AD patients (25).
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Flavonoids, polyphenolic compounds found in plants, are regularly used in
traditional medicine. Often cited at anticancer agents, recent studies in humans and
animals have also suggested that flavonoids may prevent or delay
neurodegeneration, especially in elderly populations (6). Orientin is a flavonoid
compound that has anti-inflammatory and antioxidant properties. The data obtained
by Linju Yu, et.al. showed that Orientin activated the Nrf2/HO-1 signaling. Thus,
increased the levels of HO-1, increased the levels of Nrf2 and decreased levels of
Keap1 inhibitor were observed. This decreased the β-amyloid-induced apoptosis in
the brains of the transgenic mice. There was a decrease in overall neuronal death,
reduction in ROS, and alleviation of memory and learning deficits. The results of this
study suggest that Orientin might be a potential drug treatment for AD in the future
(25).
Treatment Aimed at Alleviating Oxidative Stress: Hesperidin
Hesperidin, a flavonoid found in citrus fruits, is already known to possess
antifungal, antiviral, anti-inflammatory, and anticancer properties. In the in vitro
studies, Hesperidin has also been shown to act as an antioxidant by scavenging for
free radicals. Previous studies indicate that Hesperidin improved glucose utilization
and protected neurons against β-amyloid-induced neuronal damage. In the paper by
Dongmei Wang, et al., they look at how long term use of hesperidin affected
memory loss, mitochondrial function, and oxidative damage in mouse models (26).
In summary, this study concluded that hesperidin reduced cognitive deficits
and enhanced learning and memory in the mice. A reduction of oxidative damage
was also demonstrated by the decrease in levels of hydrogen peroxide and
malondialdehyde (MDA), both markers for oxidative stress. In addition, an increased
level of glutathione was found in cells of the mice treated with Hesperidin compared
to the control mice. Furthermore, the function of the mitochondria was restored,
particularly in the electron transport chain enzymes, complexes I-IV. The exact
mechanism underlying these effects is still unknown. However, it is most likely due
to the antioxidant properties or alterations to the mitochondria (26).
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Conclusion
The evidence presented in all the literature that was reviewed strongly
supports the idea that the vicious cycle of oxidative stress plays a key role in nearly
all aspects of AD. Oxidative stress damages mitochondria, inhibiting and altering
their function. This further induces the formation of ROS. Possibly as an effort to
compensate for oxidative damage, APP processing is pushed toward the formation
of β-amyloid proteins. There is evidence that β-amyloid, which have also been
shown to promote oxidative stress, causes the hyperphosphoylation of tau proteins.
In addition, the β-amyloid disrupts the Ca2+ signaling in the brain, subsequently
causing depletion of GSH antioxidants. The depletion of GSH further inhibits the
ability of the brain to prevent oxidative damage. Thus, there is extensive evidence
indicating the oxidative stress plays a significant role in Alzheimer’s Disease. A
summary of the role ROS plays in AD is outlined in the following figure:
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ROS

Mitochondrial
dysfunction
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Lipid
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The damage caused by oxidative stress, to the neurons, leads to protein
oxidation, lipid oxidation, and DNA damage. All of these result in an increase in
apoptosis, also seen in patients with AD. Proposed AD treatments aimed at
mediating the mitochondrial damage and oxidative stress by the antioxidants
Orientin and Hesperidin show significant results and promise for effective treatments
for AD in the future.
My biochemistry classes, and my previous laboratory experience studying the
effects of oxidative stress on HeLa cells, initially got me interested in the topic of
oxidative stress. Oxidative stress is a known contributor to the progression of many
diseases. Because Alzheimer’s Disease is such a growing problem in the United
States, I wanted to learn more about how oxidative stress contributed specifically to
its pathology. Throughout the process of finding and reading these research papers,
I learned how to effectively and efficiently digest, organize, and process the scientific
information. Writing this senior honors project and presenting the information at the
Celebration of Scholarship gave me invaluable experience in successfully
communicating information to a wide variety of audiences. Furthermore, presenting
the research paper about Orientin treatment by Linju Yu, et al. in my Honors
Biochemistry 3 class allowed me to take the time to do an in depth study of the
methods, results, and conclusions reached by the scientists. In summary, this
literature review on the scientific evidence behind AD and oxidative stress led me to
conclude that oxidative stress is a major contributor to, and result of, Alzheimer’s
Disease.
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